As per our recent research report, the size of the Asia Pacific Digital PCR and qPCR Market was worth USD 676 million in 2019 and is expected to grow at a rate of 8.9% to reach USD 1.039 billion in 2025.
Over the past decade, demand has steadily increased in the APAC Digital PCR and qPCR market, due to the increased use of genomic analysis techniques (microbiological identification and gene mutation detection) in the diagnosis of major infectious diseases (HIV, tuberculosis, malaria, hepatitis, staphylococci, etc.) and genetic disorders (such as cancer and syndromes). The increased global prevalence of target organisms, coupled with the effectiveness of qPCR and dPCR assays in the diagnosis and estimation of pathogenic microorganisms, has facilitated the use of clinical diagnostic tests (including qPCR and dPCR assays) and Asia-Pacific market growth. According to UNAIDS, about 36.9 million people worldwide are affected by HIV/AIDS as of 2017, with an average mortality of 900,000. Of these, 1.8 million new cases of HIV infection were reported in 2017 alone. In 2017, approximately 6.4 million new cases of TB were registered worldwide (WHO data, 2019), and as of 2018, about 219 million patients worldwide have malaria, and 92% of cases were registered in WHO Africa alone.
The technical shortcomings of dPCR and qPCR and the high cost of advanced PCR equipment have limited the growth of the digital PCR (dPCR) and real-time PCR (qPCR) in the Asia-Pacific market.
The typical PCR analysis with dPCR instruments involves a variety of integrated technologies (PCR, microfluidics, and nanofabrication) to achieve the desired process results. These devices are small and have short cycle times. However, the development of such devices requires significant capital investment and extensive scientific validation at the nanometer level.
A key driver of APAC Digital PCR and qPCR market growth is the increasing incidence of infectious and genetic diseases worldwide. Also, advances in PCR technology and the continuous development of PCR-based research activities complement market growth. Besides, the transition from undeveloped areas and plant-based drugs to genomic-based drugs will support growth in the digital PCR (dPCR) and real-time PCR (qPCR) market.
This research report is segmented & sub-segmented into the following categories:
Regionally, The extensive research and development activities of the leading pharmaceutical companies are supporting the business growth of digital PCR and qPCRs in the Asia Pacific region. The presence of healthcare providers, government plans for better molecular diagnostics in disease diagnosis, and continuous improvement in diagnostic reimbursement programs are expected to drive the regional market from 2019 to 2024. The emergence of automated PCR equipment, a high level of understanding of the latest medical technologies, high purchasing power, and affordability could drive the Asia Pacific dPCR and qPCR markets. Also, the growing elderly population is anticipated to drive market growth in the region.
Furthermore, factors expected to drive the Asia-Pacific market include improved healthcare infrastructure, increased private and public investment in life sciences research, and technological advances in countries such as China and India. The region is about to witness the fastest compound annual growth rate of 11% during the forecast period. Increased use of PCR in disease diagnosis is also foreseen to drive market growth in the region, as R & D expenditures are rising due to significant economic development. Countries such as China, Japan, India and others are presumed to become potential markets with evolving medical diagnostic infrastructure and high healthcare spending.
Some of the key companies dominating the APAC Digital PCR and qPCR market are Thermo Fisher Scientific Inc., F Hoffman-La Roche Ltd., Bio-Rad Laboratories, Qiagen N.V., Taraka Bio Inc., Affymetrix Inc., Agilent Technologies Inc., Fluidigm Corporation, Danaher Corporation, and Becton & Dickson Company.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.1 Consumables & Reagents
5.1.4 Y-o-Y Growth Analysis, BY Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Produt
5.2.2 Quantitative PCR
5.2.3 Digital PCR
5.2.3 Y-o-Y Growth Analysis, By Technology
5.2.4 Market Attractiveness Analysis, By Technology
5.2.5 Market Share Analysis, By Technology
5.3.2 Blood Testing
5.3.3 Pathogen Detection
5.3.4 Research & Forensic
5.3.5 Y-o-Y Growth Analysis, By Application
5.3.6 Market Attractiveness Analysis, By Application
5.3.7 Market Share Analysis, By Application
5.4 End User
5.4.3 Research & Forensic centers
5.4.4 Pharmaceutical & Biotechnological centers
5.4.5 Academic Centers
5.4.6 Y-o-Y Growth Analysis, By End User
5.4.7 Market Attractiveness Analysis, By End User
5.4.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Product
220.127.116.11 By Technology
18.104.22.168 By Application
22.214.171.124 By End User
6.1.4 Market Attractiveness Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Product
184.108.40.206 By Technology
220.127.116.11 By Application
18.104.22.168 By End User
6.1.5 Market Share Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Product
188.8.131.52 By Technology
184.108.40.206 By Application
220.127.116.11 By End User
6.5 South Korea
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Thermo Fisher Scientific Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 F Hoffman -La Roche Inc.
8.3 Bio-Rad Laboratories
8.4 Qiagen N.V.
8.5 Taraka Bio Inc.
8.6 Affymetrix Inc.
8.7 Agilent Technologies Inc.
8.8 Fluidigm Corporation
8.9 Danaher Corporation
8.10 Bector & Dickson Company
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures